MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $0 a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 net receivables of $0 is the 4th highest of the 11 companies compared; the peer median is $0.
- Net receivables amounts to 0.0% of total assets for MPLT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $22.1M | +75.1% | +41.0% | 7.9% | |
| Dec 2025 | $844K | -67.0% | -36.7% | 0.6% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $58K | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | +143.2% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding MPLT) | $0 | +4.1% | +41.0% | 0.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.